SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~September~~February 288, ~~2016~~2017

REJUVEL BIO-SCIENCES, INC.

(Exact name of Company as specified in its charter)

Florida	0-53698	27-1116025
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	15800 Pines Blvd. Suite 3116 Pembroke Pines, Florida 33027
	(Address of principal executive offices)
	(800) 670-0448
	(Company’s Telephone Number) Chase Bank Building 150 SE 2nd Ave, Suite 403 Miami, Florida 33131 (Former name or former address, if changed since last report)
	(Company’s Telephone Number) _________________________________________ (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~SECTION ~~3.02~~5 –- ~~UNREGISTERED~~CORPORATE ~~SALES~~GOVERNANCE OFAND ~~EQUITY SECURITIES~~MANAGEMENT

~~Effective September 28, 2016, the Board of Directors of~~ Rejuvel Bio- Sciences, Inc., ais ~~Florida~~referred ~~corporation~~to ~~(the~~herein as “~~Company~~our”), ~~with~~“we” ~~the~~or ~~approval of a majority of its shareholders by written consent, approved the issuance of 17,253 shares of Series A Preferred Stock at a price per share of $2~~“us”.~~898,~~ ~~to our President and Director, in exchange for the cancellation of $50,000 of indebtedness.~~

~~Effective~~Item ~~September~~5.02 ~~28,~~Departure ~~2016, the Board~~ of Directors ofor ~~Rejuvel~~Certain ~~Bio-Sciences,~~Officers; ~~Inc.,~~Election ~~a Florida corporation (the “Company”), with the approval~~ of aDirectors; ~~majority~~Appointment of ~~its~~Certain ~~shareholders~~Officers; byCompensatory ~~written~~Arrangements ~~consent, approved the issuance~~ of ~~6,896,552~~Certain ~~shares of Series C Preferred Stock at a price per share of $0.0029, to our President and Director, in exchange for the cancellation of $20,000 of indebtedness.~~Officers

~~Effective~~On ~~November~~February 18, ~~2016~~2017, ~~the~~Joseph ~~Board~~Pavlik ofwas ~~Directors~~appointed ofas Rejuvel Bio-Sciences, Inc., a Florida corporation (the “Company”), with the approval of a majority of its shareholders by written consent, approved the issuance of 330,000,000 shares of Common Stock at a price per share of $0.001, to our ~~President~~Chief ~~and~~Executive Officer/Director, inreportable ~~exchange~~under ~~for~~Item ~~the~~404(a) ~~cancellation~~ of ~~$330,000~~Regulation ~~of indebtedness~~S-K.

WeOn ~~claim~~February ~~an exemption from registration afforded by Section 4(2) of the Securities Act of 1933~~8, ~~as amended (the “Act”) since the foregoing issuance did not involve a public offering~~2017, ~~the~~Matthew ~~recipient~~Cohen ~~took~~was ~~the~~appointed securities for investment and not resale, the recipient took securities in exchange for other securities already held in the Company, we took appropriate measures to restrict transfer, and the recipient had access to similar documentation and information as ~~would~~our beChief ~~required~~Financial ~~in a Registration Statement under the Act~~Officer/Director. ~~No underwriters or agents were involved in the foregoing issuance and the Company paid no underwriting discounts or commissions.~~

~~Item~~Joseph ~~5.03 – AMENDMENT TO ARTICLES OF INCORPORATION OR BYLAWS~~Pavlik

OnJoseph ~~October 29~~Pavlik, ~~2016,~~age ~~the~~43 ~~Company~~has ~~filed~~over a20 ~~Certificate~~years of ~~Amendment~~professional ~~with~~experience in the ~~Florida~~nutraceutical, ~~Secretary~~dietary ofsupplement ~~State~~and toperformance ~~increase~~nutrition ~~its~~industry. As ~~authorized~~an ~~capital~~author, ofproduct ~~its~~development ~~common~~specialist ~~stock~~and tonutritional ~~One Hundred Billion (100~~scientist,~~000,000,000)~~ ~~shares~~he’s ofcontributed ~~Common~~multiple ~~Stock,~~product ~~par~~innovations ~~value~~to ~~$0.001~~several ~~per~~health ~~share.~~and ~~The~~wellness ~~Increase~~categories inincluding ~~Authorized was effective with the Florida Secretary of State on October 29~~anti-aging, ~~2016~~energy, ~~when~~cognitive ~~the~~enhancement, ~~Certificate~~weight ofloss, ~~Amendment~~sports ~~was~~performance ~~filed. The Increase in Authorized was approved by the Board of Directors~~ and ~~the shareholders holding a majority of the total issued and outstanding shares of common stock on October 28, 2016~~recovery.

~~SIGNATURE~~For over a decade Mr. Pavlik has assisted numerous companies in multiple capacities in the health and fitness industry as a chief consultant, product formulator, copywriter and advisor. From January of 2004-December 2005 Mr. Pavlik served as National Sales Manager for Sylvester Stallone’s Instone Nutrition Company located in Irvine, California, where he influenced research and product development. From January 2006 to December 2009, Mr. Pavlik served as Senior Vice President of Sales and Marketing for Spectrum Group Inc. located Beverly Hills, California, where he led new product development, marketing, sales and global distribution.

~~Pursuant~~Since January 2010 to ~~the~~date ~~requirements~~Mr. ofPavlik ~~the~~has ~~Securities~~served ~~Exchange~~as ~~Act~~CEO and President of ~~1934~~The Flexus Group, asa ~~amended~~private consulting firm he founded in Fort Lauderdale, ~~the~~Florida. Mr. ~~Company~~Pavlik ~~has~~received ~~duly~~a ~~caused~~B.A. ~~this~~in ~~report~~Business toAdministration befrom ~~signed~~Baldwin onWallace ~~its~~College, ~~behalf~~in byBerea, ~~the~~Ohio ~~undersigned~~in ~~hereunto~~1997 ~~duly~~and ~~authorized~~studied Exercise Physiology at Kent State in Kent, Ohio until 2003.

~~Rejuvel~~Matthew ~~Bio-Sciences, Inc. Date: November 10, 2016 By: /s/ Charles J. Scimeca Charles J. Scimeca President and CEO~~Cohen

Matthew Cohen, age 58, has served in a number of From March 2009 to July 2012, Matthew Cohen was the Chief Financial Officer of Latitude Solutions, Inc. (“Latitude”), a Nevada firm located in Dallas Texas. He also was Latitude’s Director from April 2010 to July 2012. From July 2008 to June 2009, Matthew Cohen was the Chief Financial Officer of Cavit Sciences, a publicly traded company. From July 2004 to June 2006, he was the Chief Executive Officer/Chief Financial Officer/Director of Genio Group, Inc., a publicly traded company. Mathew Cohen also served as the Chief Financial Officer for several companies across a variety of industries, including: (a) Sea Aerosupport, Inc., a company in the business of air/sea support (June 2004 to July 2006); (b) Life Imaging Corporation, a diagnostics services provider (September 2002 to December 2003); (c) Interactive Technologies.com, Ltd., a publicly traded benefit and services company (1999-2002), where he continues today as a member of its board of directors; (d) Kerr Utility, Inc. (2013 to 2015); and (e) Earth Science Tech, Inc., a hemp sciences company (2015) where he also was acting Chief Executive Officer (May 2015 to November 2015) . Mr. Cohen received a B.B.A. degree in Accounting from New Paltz State University, New York in 1980. Mr. Cohen was CFO for Kerr Utility, Inc. from 2013 to early 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Rejuvel Bio-Sciences, Inc.

Date: February 28, 2016

By: /s/ Charles J. Scimeca

Charles J. Scimeca

President

Filing Compare · REJUVEL BIO-SCIENCES, INC.